Loading...

VNRX VOLITIONRX LTD Investments/Divestments 8-K Filing

VLTN

VNRX

VOLITIONRX LTD

(VNRX)

2024 8-K

Show Summary

Summary

Financial Results Announcement

Equity Offerings

Increase in authorized shares

Financial Statements

Share Sale Agreement

Stock Registration

Financial Results

Management Appointment

Director Appointment

Management Changes

Oncology Portfolio

Financial Results

Annual Meeting Approval and...

Earnings Reports

Financial Results and Busin...

Financing Round

Amendment to Stock Incentiv...

Agreement for Public Offering

External Links:

VolitionRx received $13.0 million milestone payments from Heska Corporation for successful assay transfer of Nu.Q Vet Cancer Test onto Heska's Element i+ Immunodiagnostic Analyzer.

AI Assistant

VOLITIONRX LTD

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.